The Mouse B-raf Gene Encodes Multiple Protein Isoforms with Tissue-specific Expression*

(Received for publication, March 7, 1995, and in revised form, June 12, 1995)

Jean Vianney Barnieri, Catherine Papin, Alain Eychène, Odile Lecoq, and Georges Calothy

From the Unité Mixte de Recherche 146 du CNRS, Institut Curie, Centre Universitaire, Laboratoire 110, 91405 Orsay Cédex, France

The c-Rmil/B-raf proto-oncogene is a member of the mil/raf family encoding serine/threonine protein kinases shown to be involved in signal transduction from the membrane to the nucleus. We isolated from a mouse brain library B-raf cDNAs containing a previously unidentified 36-base pair alternatively spliced exon located between exons 8 and 9 and, therefore, designated exon 8b. Human and mouse B-raf mRNAs also contain the 120-base pair alternatively spliced exon 10 previously described in the avian c-Rmil gene. Independent splicing of these two exons, located between the conserved region 2 (CR2) and the catalytic domain (CR3) gives rise to mRNAs potentially encoding four distinct proteins. By using specific sera generated against different portions of B-Raf, we identified at least 10 protein isoforms in adult mouse tissues. Some isoforms, in the range of 69–72 kDa, are not recognized by antisera directed against peptides encoded by exons 1 and 2, indicating the existence of B-Raf proteins with two different NH2 extremities. The other isoforms, in the range of 79–99 kDa, contain the amino acids encoded by exons 1 and 2, by either or both of the alternatively spliced exons, and, possibly, by another unidentified exon. Analysis of B-raf mRNA expression by reverse transcriptase-polymerase chain reaction and immunoocharacterization of B-Raf proteins in different tissues of the adult mouse showed a tissue-specific pattern of B-Raf isoforms expression. Interestingly, isoforms containing amino acids encoded by exon 10 are specifically expressed in neural tissues. Taken together, these results suggest that distinct B-Raf proteins could be involved, in a tissue-specific manner, in signal transduction pathways.

Proto-oncogenes of the mil/raf family encode serine/threonine protein kinases, which act as signal transducers downstream of receptors to nuclear transcription factors (1, 2). Members of the Raf family play a major role in the regulation of cell proliferation and are also required for the determination of cell fate during embryogenesis (3, 4). The p72/74 Raf-1 protein encoded by the c-raf/c-mil gene is ubiquitously expressed in embryonic and adult mouse tissues. This protein has been shown to act downstream of Ras and upstream of MAP kinase kinase (Mek-1) in mammalian and invertebrate cells (1). Raf-1 associates with the GTP-bound Ras protein, the activated form of p21

* This work was supported by the Centre National de la Recherche Scientifique, the Institut Curie, and a grant from the International Human Frontier Science Program Organization. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡Present address: Inst. A. Fessard, UPR 2212 du CNRS, Bâtiment 33 91198 Gif-sur-Yvette, France. To whom reprint requests should be addressed: Inst. Curie-Biologie, Laboratoire 110, Centre Universitaire, 91405 Orsay Cedex, France. Tel.: 33-1-69-86-30-78; Fax: 33-1-69-07-45-25.
cDNAs of an alternatively spliced exon of 120 bp (exon 10) located upstream of the kinase domain (27) between exons 9 and 11 according to the genomic organization of the coding region of the chicken c-Rmil/B-raf gene (28). However, the presence of a similar and of other alternatively spliced exons in mammals remained to be investigated. Therefore, we undertook a detailed analysis of the molecular diversity of mammalian B-raf proteins and of their tissue distribution in order to gain new insights into the specific implications of this gene in signal transduction.

We describe here the molecular cloning and sequencing of several mouse B-raf cDNAs differing by the presence of two alternatively spliced exons. We show that the mouse B-raf gene not only contains the 120-bp alternatively spliced exon 10 previously described in avian DNA but also another alternatively spliced exon of 36 bp, located between exons 8 and 9 (exon 8b). The expression pattern of the various B-raf transcripts in adult mouse tissues was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). We also identified at least 10 B-raf protein isoforms in these tissues by using specific antisera directed against different portions of B-raf. These isoforms differed by the presence of the alternatively spliced exons 8b and 10, by their NH2 extremities, and possibly by the presence of other unidentified sequences. Each isoform exhibits a specific pattern of expression in the adult mouse tissues analyzed, those containing amino acids encoded by exon 10 being specifically found in the central nervous system.

EXPERIMENTAL PROCEDURES

Isolation and Characterization of Mouse B-raf cDNAs Containing Alternatively Spliced Exons—B-raf cDNA clones were amplified from an adult mouse brain library constructed in the λ Zap vector by PCR using a mouse exon 17-specific antisense oligonucleotide, O9 (5'-GTAAGTCGACGATGTTACCTGGATCCCTTAC), and a T3 promoter-specific oligonucleotide. A second amplification was done using an exon 14-specific antisense oligonucleotide, O2 (5'-CATATGCGAAGCTTACATCGTGGCGTCTCTCTCAGG), and a Bluescript SK vector. PCR products were purified, digested with BamHI and SalI enzymes, and subcloned into the BamHI-SalI sites of the Bluescript vector (Stratagene, La Jolla, CA).

300 ng of poly(A)+ RNAs from adult mouse brain or 1 μg of mRNA from adult mouse tissues were reverse transcribed by priming with random hexamers using avian myeloblastosis virus reverse transcriptase (Amersham Corp.). Locations of B-raf-specific primers are indicated in Figs. 1, 2, and 4. Amplifications were done with the following primers, the location of which is indicated in the figures: O3 (5'-GATGCTGACAGCATCCTGATCTC), O2 (5'-GTCGACGACTCCACAACTC), O4 (5'-GATGCGAAGAAATCCCAAGTGGG), O5 (5'-GACTGTGACGATCGCTTCTATCGTGGCTATCGTGC), and O10 (5'-GTCGACCGACCCATAAACTCGCAGAC). Southern blots of PCR products, separated on a 2% agarose gel, were done using standard procedures (32) and hybridized with 5'-end-labeled oligonucleotides, specific to the exon 8 sequence (O257, 5'-CGACGAGCAGATGAAGATG) or with O11. The B-raf gene was analyzed by PCR using 100 ng of genomic DNA from NIH3T3 cells as a template in a standard reaction, with the same couple of oligonucleotides O2O11 and O10O10 PCR products were cloned in the pUC18 vector and partially sequenced using vector-specific primers.

Total cellular RNA preparations were obtained by the single step method using acidic guanidinium thiocyanate (33). RT-PCR analysis of mouse and human exon 10 were done for the 36-bp exon 8b, except that the following oligonucleotides were used: O8 (5'-GAGACAGCAGGGTTTCTGG), O10 (5'-CATCCGCAGTCTCCATCCGCTTC), O11 (5'-CAGGGCTCAGGCGTAATTGA), O12 (5'-CGGACCACTCCATCCTC), and O13 (5'-CCCCCTGGAACACTACCATG). RT-PCR analysis of tissue-specific expression of the different B-raf transcripts was performed using standard procedures, as described under "Results," using the oligonucleotides described above and O14 (5'-CAGGGCAGTCGAACACACTCGG), O15 (5'-GTTTCTGAGGACCTTTGG), O16 (5'-GGTCTGAGGAGAACCTACGATCCAGGGCTCAAAATCAAA).

RESULTS

The Presence of Two Alternatively Spliced Exons in the Mouse B-raf Gene Generates Multiple B-raf Transcripts—A partial sequence of the mouse B-raf gene was reported by Miki et al. (38), who isolated its catalytic domain by using a cDNA expression cloning system. To identify the B-raf gene products, we first cloned B-raf cDNAs using PCR-aided amplification of an adult mouse brain cDNA library. PCR-amplified products were subcloned and analyzed by restriction mapping and sequencing. We found that some clones differed by the presence of an additional sequence of 36 bp (Fig. 1A). These 36 nucleotides, which are in frame with the remaining B-raf coding sequence, are located between exons 8 and 9, according to the genomic
organization of the avian c-R
mil gene (28) (Fig. 1A).

We searched for the presence of this sequence in adult mouse brain B-raf RNAs using RT-PCR, as described under “Experimental Procedures.” We amplified two fragments of 157 and 193 bp with oligonucleotides O5 and O8 specific to exons 8 and 9, respectively (Fig. 1B). Both fragments hybridized with an oligonucleotide specific to exon 8 (data not shown), but only the largest one hybridized with the oligonucleotide O2 specific to the 36-bp insertion. Amplifications with specific primers (O5/O6 and O7/O8) confirmed these results (Fig. 1B). These observations established the existence of B-raf transcripts containing this 36-bp additional sequence.

Since this inserted sequence occurred at the junction between exons 8 and 9, we analyzed the genomic organization of the mouse B-raf gene region between exons 8 and 9. NIH3T3 DNA was amplified under standard conditions with O5/O6 and O7/O8, and PCR fragments were subcloned and sequenced. Exonic sequences are indicated by capital letters, and intronic sequences are indicated by lowercase letters.

The B-raf Gene Encodes Multiple Isoforms

We previously described an alternatively spliced exon of 120 bp in the avian c-Rmil gene, located between exons 9 and 11 (27). We investigated the expression of this exon in adult mouse brain mRNA by RT-PCR. Using two oligonucleotides located in the exons 9 (O9) and 11 (O10), we amplified a fragment of 156 bp, which hybridized with O9. Using O9 and O10, we obtained a fragment of 73 bp, which hybridized with O9. C DNA structure and genomic analysis of the mouse B-raf gene region between exons 8 and 9. 100 ng of DNA from NIH3T3 cells were amplified under standard conditions with O9/O10 and O7/O8, and PCR fragments were subcloned and sequenced. Exonic sequences are indicated by capital letters, and intronic sequences are indicated by lowercase letters.

The diversity of B-raf mRNA isoforms in the region encompassing exons 8b and 10 was investigated by RT-PCR. Using oligonucleotides O9 and O10 specific to exons 8 and 11, respectively,

![Fig. 1. Identification of a B-raf alternatively spliced exon of 36 bp (exon 8b).](image-url)
The B-raf Gene Encodes Multiple Isoforms

and total RNAs from spinal cord as a template, we amplified four distinct fragments of 300, 336, 420, and 456 bp (Fig. 3A). The 420- and 456-bp fragments hybridized with an oligonucleotide specific to exon 10, whereas the 336- and 456-bp fragments hybridized with a labeled oligonucleotide specific to exon 8b (data not shown). Thus, the 300-bp fragment contains exons 8, 9, and 11; the 336-bp fragment contains exons 8, 8b, 9, and 11; the 420-bp fragment contains exons 8, 9, 10, and 11; and the 456-bp fragment contains all five exons (Fig. 3A). These results show that the two alternatively spliced exons are present either together or separately on the same mRNA, suggesting that the B-raf gene is transcribed into at least four distinct mRNAs, designated B1 to B4 (Fig. 3B).

Tissue-specific Distribution of Mouse B-raf Transcripts—Previous reports indicated that the c-Rmil/B-raf gene displays a restricted pattern of expression (13, 14). To delineate the expression patterns of the alternatively spliced exons of the B-raf gene, we analyzed a variety of adult mouse tissues, by RT-PCR using oligonucleotides, the location of which is indicated in Fig. 4A. The number of exons, which differs between combinations of exons, was chosen to optimize signal comparison between the different tissues.

Tissue distribution of B-raf mRNAs was first investigated by using oligonucleotides specific to the catalytic domain, since this domain was shown not to be subjected to alternative splicing (Fig. 4B). We found that B-raf gene expression was rather

![Fig. 2. Identification of the mammalian B-raf alternatively spliced exon 10. A, a schematic representation of a partial B-raf exon 10-containing cDNA between exons 9 and 11. Oligonucleotides used for PCR amplification are indicated, in the upper line for mouse cDNA amplification and in the lower line for human cDNA amplification. The genomic organization was deduced from that of the chicken c-Rmil gene (27, 28). B, RT-PCR amplification of adult mouse B-raf mRNAs. 1 μg of brain mRNA was reverse-transcribed, and 1/20 of the first strand (lane 2) was amplified between O9 and O10 or O23 and O10. The same primers were used with a control of reverse-transcribed water (lane 1). Size markers are indicated in bp (lane 3). Products were analyzed on a 2% agarose gel. C, RT-PCR amplification of human B-raf mRNA. RT-PCR was done with water (lane 1) or with human mRNAs (lane 2) as template, using O24/O17 or O23/O10 primers. Products were analyzed on a 2% agarose gel. D, comparison of nucleotide sequences of partial cDNAs containing exon 10, from quail, mouse, and human. The chicken coding sequence corresponds to that of the genomic DNA (28). E, comparison of deduced amino acid sequences from avian Rmil and mammalian B-Raf proteins. The sequences of exon 10 are overlined.

![Fig. 3. The B-raf gene potentially encodes four B-Raf isoforms. A, RT-PCR amplification of mouse brain mRNA between exons 8 and 11. 1 μg of mRNA (lane 3) or water (lane 2) was reverse-transcribed and amplified with O8/O10 primers and analyzed on a 2% agarose gel. Lane 3, size markers are indicated in bp. Designation of the corresponding isoforms is indicated on the right. B, partial protein structures of the B-Raf isoforms between exons 8 and 11. The size of exons is indicated on the first line.]
The B-raf Gene Encodes Multiple Isoforms

**Figure 4. Analysis of tissue-specific expression of the B-raf transcripts by RT-PCR.** The structure of the B-raf transcripts and location of primers used for PCR are illustrated on the first line (A). One μg of total RNA from 14 tissues was reverse-transcribed using random hexanucleotide primers, and 500 ng of the first strand cDNA was amplified with specific primers indicated on line A. The amount of RNA and quality of the first strand were verified using specific primers of the mouse β-actin gene (data not shown). Adult mouse tissues are as follows: total brain (lane 2), cerebral hemispheres (lane 3), midbrain (lane 4), cerebellum (lane 5), cervical spinal cord (lane 6), dorsal spinal cord (lane 7), eye (lane 8), kidney (lane 9), ovary (lane 10), testis (lane 11), spleen (lane 12), thymus (lane 13), liver (lane 14), muscle (lane 15), heart (lane 16), lung (lane 17). Lane 1 is a control with reverse-transcribed water. Amplifications were done between the following: the kinase domain, O1/O4, with 25 cycles and hybridized with labeled O2 (C); exon 8b, O5/O6, with 33 cycles and hybridized with labeled O7 (D); exon 8b and 10, O23/O10, with 33 cycles and hybridized with O17 (E); and exons 8 to 11, O10/O17, with 30 cycles, and hybridized with O9 (F).

**Figure 5. Characterization of four anti-B-Raf sera.** Top, schematic representation of the B-Raf protein, indicating the positions of the Raf family conserved regions, the two alternatively spliced exons (8b and 10), and the location of peptides used for immunizations. Peptides encoded by exons 1 and 2 and exon 10 were fused to a bacterial MSII polyepipease and purified. The 12-amino acid peptide encoded by exon 8b was synthesized and coupled to thyroglobulin, as a carrier, before injection to rabbits. Bottom, summary of the designation of sera and the structure of antigens used for immunization. The properties of each serum to immunoprecipitate (IP) and/or recognize the avian or murine (chimeric constructs) Rmil/B-Raf proteins by Western blotting (WB) are indicated on the right.

Variable, depending on the tissue. High levels of B-raf transcripts were detected in the nervous system, especially in the midbrain and dorsal spinal cord (lanes 4 and 7). In the total eyes (lane 8), B-raf mRNA is present at an intermediate level, whereas our previous reports showed that this mRNA was expressed at a high level in the neoretrina (14). This could be explained by the fact that the neoretrina constitutes only a very small proportion of this organ. High levels of B-raf were also found in gonads, particularly in testes (lane 11), whereas the kidney, spleen, thymus, liver, and heart (lanes 9, 13, 12, 14, and 16) contained intermediate levels of these transcripts. Finally, B-raf was barely detectable in the muscle (lane 15) where 35 cycles of amplification are necessary to detect it (data not shown).

Analysis of the expression of B-raf transcripts containing exon 8b was done following 33 cycles of amplification (Fig. 4C). We found that this exon is widely expressed, but its distribution differs from that of the catalytic domain. Thus, in the central nervous system, exon 8b is highly expressed in the cerebral hemispheres and cerebellum (lanes 3 and 5), whereas its expression is lower in the midbrain and spinal cord (lanes 4 and 6). Interestingly, exon 8b is also found at a moderate level in heart, ovaries, testes, and spleen (lanes 16, 10, 11, and 12).

Exon 10 displayed a more restricted pattern of expression (Fig. 4D). It is very abundant in neural tissues (lanes 2-8) in a rather uniform manner and is also detected in the heart and testes (lanes 16 and 11, respectively). Analysis of the B4 transcript expression was performed by amplification between a forward oligonucleotide located in the 5′-end of exon 8b and a reverse primer specific to the 3′ extremity of exon 10 (Fig. 4E). Expression of this transcript was restricted to parts of the central nervous system, specifically the mesencephalon and metencephalon (lane 4). We also detected a weak expression in other neural tissues and in the heart.

Expression of the B1 transcript, which does not carry an alternatively spliced exon, was analyzed by RT-PCR (30 cycles) between the forward exon B-specific primer (O5) and the reverse exon 11-specific primer (O17) (Fig. 4F). PCR products were hybridized with an oligonucleotide specific to the constitutively expressed exon 9. We obtained the expected four fragments corresponding to B-raf transcripts, which were molecularly characterized. We observed a slight decrease in the amplification efficiency for the large fragments corresponding to the B3 and B4 encoded transcripts. The B1 transcript was widely expressed in adult mouse tissues but was the unique form detected in some tissues such as the kidney, thymus, liver, and lung (lanes 9, 13, 14, and 17), after 30 cycles of amplification. This transcript was the predominant one in testes and ovaries (lanes 10 and 11), whereas its level was lower than that of the B2 form in neural tissues and in the heart (lanes 2-8 and 15).

Characterization of Specific Sera Directed against Exons 1 and 2 and Alternatively Spliced Exons 8b and 10—We previously described an immune serum (IS11) directed against avian Rmil amino acids encoded by exon 11 that do not display similarity with other Raf proteins (27). This serum specifically immunoprecipitates and recognizes on Western blots the avian Rmil and the mammalian B-Raf proteins. However immunoccharacterization of B-Raf proteins with IS11 alone did not allow us to identify the different isoforms. Therefore, we prepared antisera against amino acids encoded by the two alternatively spliced exons 8b and 10, to identify B-Raf proteins containing these exons. These immune sera were designated IS8b and IS10. We also prepared an antiserum directed against the amino acids encoded by exons 1 and 2 of the quail Rmil protein in order to confirm the presence of this sequence in B-Raf proteins. The strategy and the structure of the antigenic proteins used to prepare these immune sera are summarized in Fig. 5.

The antisera were tested for their ability to recognize the specific isoforms by immunoprecipitation and Western blotting. Therefore, we transfected COS-1 cells with plasmids encoding the different B-Raf isoforms, and we analyzed their
The B-raf Gene Encodes Multiple Isoforms

![Fig. 6. Characterization of three B-Raf antisera using overexpressed B-Raf isoforms.](image)

**Fig. 6.** Characterization of three B-Raf antisera using overexpressed B-Raf isoforms. COS-1 cells were transfected with pSVL vector as control (lanes 1), pSVL/C-Rmil A encoding the avian B1 isoform (lanes 2), pSVL/C-Rmil A 4K83M encoding the avian kinase-defective mutant B1 isoform (lanes 3), pSVL/C-Rmil B encoding the avian B3 isoform (lanes 4), pCP1 encoding the chimeric B2 isoform (lanes 5), pCP2 encoding the chimeric kinase-defective mutant B2 isoform (lanes 6), and pCP5 encoding the B3 chimeric isoform (lanes 7). Expression of the isoforms in transfected COS-1 cells was controlled by immunoprecipitation of cell lysates followed by a Western blot analysis with the same IS11 antibody. A, B, and C, specific recognition of B-Raf isoforms by the three antisera. COS-1 cells were transfected with the indicated plasmids and immunoprecipitated 48 h later with 5 μl of IS11 serum. Immunoprecipitates were analyzed by Western blotting as described under “Experimental Procedures” with immune IS11 (1:4000) or preimmune (PI, 1:4000) IS11 serum (A); immune IS11 (1:4000) or immune IS8b (1:1000) (B); and immune IS11 (1:4000), preimmune IS10 (1:1000), or immune IS10 (1:1000) (C). D, E, and F, immunoprecipitation of B-Raf isoforms. Lysates of transfected COS-1 cells were immunoprecipitated with IS1/2 (10 μl) (D); with IS8b (10 μl), its preimmune serum (PI 10 μl), or IS8b preabsorbed with 10 μg of antigen (IS8b + Ag) (E); and with IS10, preimmune IS10 (PI), or antibodies preabsorbed with 10 μg of antigen (IS10 + Ag) (F). Immunoprecipitates were analyzed by Western blotting with IS11 (1:4000).

![Fig. 7. Characterization of B-Raf isoforms.](image)

**Fig. 7.** Characterization of B-Raf isoforms. Brain (lane 1) and liver (lane 2) extracts (400 μg) were immunoprecipitated with IS11 serum (A, C, and D), IS11 preadsorbed with its antigen (B), IS10 serum, or its preimmune serum (E and F). Immunoprecipitates were analyzed on SDS-polyacrylamide gels, transferred on polyvinyl membranes, and probed with IS11 (1:4000) (A, B, and E), IS1/2 (1:1000) (C), or IS8b (1:1000) (D and F) sera. Molecular weights (69,000 and 97,000) are indicated on the right of each gel. Black arrows indicate specific B-Raf proteins; open arrows indicate nonspecific bands. The first lower line indicates the serum used for immunoprecipitation; the second line indicates the serum used for Western blotting.

![Fig. 8. Tissue-specific expression of B-Raf isoforms.](image)

**Fig. 8.** Tissue-specific expression of B-Raf isoforms. Tissue extracts (brain (A), spinal cord (B), kidney (C), testes (D), thymus (E), spleen (F), liver (G), muscle (H), heart (I), lung (J) (400 μg)) were immunoprecipitated with 5 μl of IS11 serum, and immunoprecipitates were resolved by Western blotting with IS11 (1:4000) (lanes 1), with IS8b (1:1000) (lane 2), and with IS10 (1:1000) (lane 3). Exposure time of chemiluminescence was 5 s for neural tissues and 20 s for other tissues. Molecular weights (69,000 and 97,000) are indicated on the right of each panel. Open arrows, asterisks, and open squares indicate nonspecific bands. Dark arrows indicate specific bands.

expression products 48 h later (Fig. 6). We investigated the ability of these sera to recognize B-Raf proteins in a Western blot analysis by immunoprecipitating cell lysates of transfected COS-1 cells with the IS11 serum and subsequently probing the electrophoresed proteins with each of the immune sera (Fig. 6, A, B, and C). The ability of each serum to immunoprecipitate B-Raf proteins was tested by analyzing the precipitated materials by Western blotting and probing with the IS11 serum (Fig. 6, D, E, and F). The properties of these four monoclonal sera are summarized in Fig. 5.

Immunological Characterization of B-Raf Isoform Structures—We analyzed the structure of B-Raf isoforms by immunoprecipitation and Western blotting of extracts from mouse brain and liver, using the four B-Raf-specific sera (Fig. 7). We detected low levels of two proteins of 67 and 69 kDa with the IS11 serum (Figs. 7A and 8A) but not with the IS1/2 serum (Fig. 7C). The 69-kDa protein was also recognized by the IS8b serum. These 67-69 kDa proteins were more easily detectable in Western blots upon longer exposure (Fig. 8, A (lane 1), and B (lane 1)). The other B-Raf proteins, with apparent molecular weights ranging between 79,000 and 99,000 reacted with both the IS11 and the IS1/2 sera. Taken together, these results indicate that these two 67- and 69-kDa proteins, designated short forms (SF), are B-Raf isoforms lacking most, if not all, amino acids encoded by exons 1 and 2.

In addition, we detected in brain but not in liver extracts proteins that are specifically recognized by the IS8b or by the IS10 serum. This showed that some B-Raf proteins contain the peptides encoded by these alternatively spliced exons, thus confirming the existence of B2 and B3 isoforms (Fig. 7, D and E). Two proteins with apparent molecular weights of 94,000 and 97,000 were immunoprecipitated with the IS10 serum and recognized by Western blotting with the IS8b serum (Fig. 6F). They correspond, therefore, to the B4 isoform. That both proteins were also recognized by the IS1/2 serum (data not shown) rules out the possibility that the difference in their apparent molecular weights could be due to an alternative NH₂ extremity and suggests the existence of an additional alternatively spliced exon(s), as yet unidentified in B-Raf cDNAs. It is also possible that they could result from post-translational modifications, such as phosphorylation. These latter isoforms are marked with an asterisk (*)

In summary, the B-raf gene encodes multiple protein isoforms, which differ by the presence of four alternatively expressed regions encoded by exons 8b and 10, the two different NH₂-terminal extremities, and, possibly, an unidentified alternatively spliced exon(s). Since these four alternative structures would potentially generate 16 isoforms, we obviously did not detect all possible B-Raf combinations. For example, the short NH₂ extremity was never found associated with the presence of exon 10. Our analysis of B-Raf proteins in liver, in brain, and in other adult mouse tissues (see below) allowed us to detect only 10 distinct B-Raf isoforms. Their designations, apparent mo-
The B-raf Gene Encodes Multiple Isoforms

The designation and apparent molecular mass of each isoform are given in the first two columns. Immunological characterization with the different sera was deduced from experiments in transfected COS-1 cells or in mouse tissues. E, exon.

| Isoform | Apparent molecular mass | Anti-E1/2 | Anti-E8B | Anti-E10 | Anti-E11 |
|---------|-------------------------|-----------|----------|----------|----------|
| SF1     | 67                      | -         | -        | -        | +        |
| SF2     | 69                      | -         | +        | -        | +        |
| B1      | 79                      | +         | -        | -        | +        |
| B2      | 82                      | +         | +        | -        | +        |
| B1*     | 86                      | +         | +        | -        | +        |
| B2*     | 88                      | +         | +        | -        | +        |
| B3      | 90                      | +         | -        | +        | +        |
| B3*     | 94                      | +         | -        | +        | +        |
| B4      | 96                      | +         | +        | +        | +        |
| B4*     | 99                      | +         | +        | +        | +        |

Molecular weights, and immunologically deduced organizations are summarized in Table I.

Expression of B-Raf Isoforms in Adult Mouse Tissues—We immunoprecipitated B-Raf proteins from 10 adult mouse tissues with the IS11 serum and analyzed them by Western blotting with each of the four specific immune sera (Fig. 8 and Table II). The highest levels of B-Raf protein expression were detected in the brain (Fig. 8A) and spinal cord (Fig. 8B), as compared with other tissues. Brain regions presented the most complex pattern of expression. They are the only tissues expressing all four alternatively spliced regions. Because of the number of detectable bands, it was difficult to precisely distinguish these proteins. In brain and spinal cord, we could detect seven and nine isoforms, respectively, with the IS11 serum, and four isoforms with the IS10 serum. The main differences between these two tissues were that the exon 8b-containing isoforms were more abundant in the spinal cord, and that the B1 and B1* forms were detected only in the spinal cord.

In other tissues, B-Raf proteins were less abundant and their expression pattern was less complex than in neural tissues. In kidney (Fig. 8C), we detected three isoforms, the major one being the short form SF1 of 67 kDa, and the B1 and B1* forms were weakly detected. Thus, the kidney does not appear to express the two alternatively spliced exons 8b and 10. Among the 10 tissues tested, the liver (Fig. 8D) had nearly the same isoform pattern of expression as the kidney, but the SF1 form was less expressed and the B1 and B1* forms were more abundant. Both B1 and B1* isoforms were moderately expressed in the thymus, which appears to be the unique tissue to express only two isoforms.

All other tissues contained B-Raf isoforms carrying the polypeptide encoded by exon 8b. In the spleen (Fig. 8F), we detected three isoforms, the most abundant being a short form of 69 kDa, which was also recognized by the IS8b serum. The two other isoforms were the B1 and B1* proteins. In the testes (Fig. 8D), a weak expression of the SF1 form was also observed. We characterized two isoforms recognized with the IS8b serum, corresponding to the B2 and B2* forms. The B1* protein was also present in this tissue.

The lung (Fig. 8) expressed moderate levels of B1, B1*, B2, and B2* and also weak levels of the SF1 isoform. The heart (Fig. 8I) is the only non-neuronal tissue to express a detectable amount of exon 10-containing proteins and also the only one that did not express the unidentified structure (*). However, the major isoform detected in this tissue was the SF1 form. We detected two proteins with the IS10 serum, one of which reacted also with the IS8b serum; thus, they corresponded to the B3 and B4 isoforms, respectively. Interestingly, we could not detect B-Raf proteins in the muscle. Taken together, our results on the expression pattern of the various B-Raf isoforms are in agreement with those obtained by RT-PCR analysis.

DISCUSSION

Molecular analysis of B-raf transcripts and immunological characterization of B-Raf proteins allowed us to identify and to characterize at least 10 B-Raf isoforms in adult mouse tissues, each of them exhibiting a particular pattern of distribution. We showed the presence of two alternatively spliced exons and proposed the existence of an additional one. This demonstrates the high degree of complexity in the structure of B-raf gene products, as compared with other protein kinases. Our results also suggest the existence of tissue-specific regulation of alternative splicing and selection of B-Raf isoforms in adult mouse tissues.

Structure of the B-Raf Isoforms—We provide evidence that two proteins with an average molecular weight of 67,000–69,000, which are recognized by B-Raf-specific immune sera, are indeed B-Raf proteins and differ from the longer forms by their amino-terminal extremities. These short forms are specifically recognized by some anti-B-Raf antibodies but not by the IS1/2 serum. We could exclude the possibility that they originate from the long isoforms by proteolytic cleavage or degradation since we did not detect them in COS-1 cells transfected with full-length cDNAs. It is possible that expression of the B-raf gene could be regulated by at least two alternative promoters, each one controlling the expression of one type of B-Raf protein. Alternatively, it may be that the two different NH2 extremities are generated by an alternative splicing mechanism.

It is likely that the 67-kDa B-Raf protein identified in PC12 cells (16, 40) and in brain extracts (23) corresponds to one of the short forms described in this study. However, we did not detect this short form in several PC12 cell line clones used in our laboratory, as also reported by Stephens (17). This discrepancy may be due to the PC12 cell clones used. Interestingly, these short forms also present a restricted pattern of distribution and appear to represent the major isoform in some tissues, such as the kidney.

Indirect evidence that the 67/69-kDa short forms possess a functional kinase domain is provided by a convergent set of data. In some PC12 and hematopoietic cell lines (16, 20) in which activation of B-Raf was studied, an increased phospho-tyrosine was detected after cytokine activation of these cells. Because of the presence of the 95-kDa protein in these cells, it was not possible to conclude whether p67/p69 possesses a kinase activity or whether it is a substrate of p95B-raf. We recently showed that a short isoform was the only B-Raf protein detected in Jurkat cells and that this protein possesses an intrinsic kinase activity, which increased after
Expression of B-Raf isoforms was deduced from Western blotting experiments described in Figs 7 and B. B, brain; SC, spinal cord; KI, kidney; TE, testes; TH, thymus; SP, spleen; LI, liver; MU, muscle; HE, heart; LU, lungs. Quantification was done by visual estimation. Blank, not detected; +, weak; ++, moderate; ++++, abundant; +++++, very abundant.

| Protein | B | SC | KI | TE | TH | SP | LI | MU | HE | LU |
|---------|---|----|----|----|----|----|----|----|----|----|
| SF1     | + | ++++ | + | + | + | ++ | + | ++ | + | + |
| SF2     | ++ | + | + | + | + | + | + | + | + | + |
| B1      | + | + | + | + | + | + | + | + | + | + |
| B2      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B3*     | +++ | +++ | + | + | + | + | + | + | + | + |
| B3      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B4      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B4*     | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |

cell stimulation (20). Moodie et al. also reported that different B-Raf proteins, with molecular weights ranging between 65,000 and 105,000, associate with immobilized p21ras-GMP-PNP (23). Taken together, these results suggest that the short B-Raf isoforms interact directly with activated p21ras protein and that this interaction apparently does not require the presence of the first two coding exons. Interestingly, the B-Raf short forms, which apparently do not contain sequences encoded by exons 1 and 2, have a structure similar to that of the A-Raf- and Raf-1-related proteins. Thus, their specific role in signal transduction remains to be elucidated.

We also identified two alternatively spliced exons, 8b and 10, encoding 12 and 40 amino acids, respectively, which do not present similarity with known protein sequences. Using specific antibodies IS8b and IS10, we identified 5 and 4 isoforms, respectively, containing these sequences and showed that both inserts can be associated on the same protein.

The 36-bp exon 8b, between exons 8 and 9, is located at a position homologous to that of the 7a alternatively spliced exon identified in the c-mil/c-raf gene (41). This 60-bp c-mil/c-raf exon encodes 20 amino acids, which are not similar to those encoded by exon 8b of the B-raf gene. Interestingly, expression of the 7a c-mil/c-raf exon is restricted to muscle and, to a lesser extent, to brain (42) suggesting that the tissue-specific exons 7a and 8b could have a specific function in signal transduction.

Exon 10, the amino acid sequence of which is conserved between avian and mammalian species, displays the more restricted pattern of expression since it was found expressed at a high level only in the central nervous system and, to a lesser extent, in heart and testes, as determined by RT-PCR. Exon 10-containing isoforms were detected with the IS10 serum in brain, which would strongly suggest that alternative splicing of this exon takes place preferentially in neural cells.

Exons 8b and 10 are located in the same region, between the CR2 and the CR3 domains of the B-Raf proteins. They are separated only by the 37 nucleotides of exon 9. This region represents a high polymorphism in B-Raf and also, to a lower extent, in Raf-1 proteins and could, therefore, correspond to a variable region in the raf gene family, as reported for calmodulin kinases (43). Our immunological data suggest that B-Raf proteins contain at least another alternatively expressed structure, which could either correspond to a post-translational modification of the protein or to a sequence encoded by an unidentified alternatively spliced exon. Extensive molecular analysis of B-raf transcripts should help to confirm this hypothesis.

Tissue Distribution of B-Raf Isoforms—Our molecular and immunological results show that the B-raf gene is highly expressed in neural tissues, such as the brain and spinal cord. In these tissues, the long forms are predominant. We did not observe a significant difference in B-raf expression in different regions of the brain, in contrast to the report of Storm et al. (13). As observed by RT-PCR, the two alternatively spliced exons 8b and 10 are highly expressed in brain, and exon 10 appears to be neurospecific. A more precise analysis of B-raf expression in the heart and in the central nervous system could confirm this hypothesis. The higher complexity in the expression pattern of B-Raf isoforms was also found in neural tissues. We detected eight and nine isoforms in the brain and spinal cord, respectively. Similar results were obtained by analyzing adult rat brain extracts (data not shown).

In other tissues, B-raf expression is also complex but quantitatively less important. We observed a relatively elevated level of B-raf transcripts and B-Raf proteins in testes as also reported by Storm et al. (13), but this expression is weaker than in neural tissues. Our results establish that other tissues express relatively weak amounts of B-raf transcripts and proteins and that expression of this gene is barely detectable in muscle. Moreover, we showed that the pattern of isoform expression is specific to each tissue.

B-Raf Isoforms and Signal Transduction—The CR1 and CR3 domains of the Raffamily proteins have been shown to interact with cellular proteins, such as Ras-GTP, the 14–3-3 proteins, mitogen-activated protein kinase (Mek) and some other proteins (8–11, 44–46). Thus far, we did not find any polymorphism in these domains of interactions, suggesting that all Raf proteins interact with the same cellular proteins. Accordingly, we confirmed that different B-Raf isoforms associate with Mek-1 and phosphorylate this protein at the two specific activating serine residues 218 and 222 (25). Recent results suggest that different B-Raf isoforms interact with activated p21ras (23). B-Raf proteins appear to constitute the major mitogen-activated protein kinase kinase kinase (Mek kinase) activity in PC12 cells (21, 22) and to be involved in activation of this kinase cascade by nerve growth factor (21). Conversely, Mek-1 activation in the brain appears to depend on the presence and association of B-Raf proteins with activated p21ras (23, 24). Taken together, these results indicate that the different B-Raf proteins act as signal transducers between Ras-GTP and Mek.

Thus, the variable region (between CR2 and CR3), which displays low similarity among members of the Raffamily, could direct interactions of B-Raf isoforms with specific effectors. There have been only few reports showing that the presence of an alternatively spliced exon could modify the properties of a kinase. The presence of a neurospecific exon in the c-Src protein increases its specific kinase activity (47). In the tyrosine kinase receptor TrkC, insertion of alternatively spliced exons results in the loss of its ability to phosphorylate phospholipase

| Protein | B | SC | KI | TE | TH | SP | LI | MU | HE | LU |
|---------|---|----|----|----|----|----|----|----|----|----|
| SF1     | + | ++++ | + | + | + | ++ | + | ++ | + | + |
| SF2     | ++ | + | + | + | + | + | + | + | + | + |
| B1      | + | + | + | + | + | + | + | + | + | + |
| B2      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B3*     | +++ | +++ | + | + | + | + | + | + | + | + |
| B3      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B4      | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| B4*     | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
Cyclin-dependent kinase (43). In calmodulin kinase, an alternative splicing introduces a nuclear localization signal that targets a calmodulin kinase isoform to the nucleus (43). Therefore, it is possible that the presence of alternatively spliced exons could modulate the B-Raf kinase activity, the specificity of its substrates, or its targeting within the cell.

It is not clear whether the B-Raf proteins are implicated in differentiating or proliferating signal transduction pathways. It is interesting that, in testes, B-raf transcripts are detected only in pachytene spermatocytes and more abundantly in postmeiotic spermatids as shown by in situ hybridization (26). We also detected B-Raf proteins more abundantly in neural tissues, where the vast majority of cells are postmitotic. These results suggest that B-Raf proteins could be involved in differentiation rather than in proliferation processes.

Acknowledgments—We thank F. Lamballe and P. Vernier for critical reading of the manuscript, A. Rotig for providing the child brain biopsy, and J. C. Cavadore for helpful advice on antibody strategies. We thank F. Arnouilh for help with the preparation of the manuscript and J. P. Bouillot and O. Champion for assistance in preparation of figures.

REFERENCES

1. Li, P., Wood, K., Mamon, H., Haser, W., and Roberts, T. (1991) Cell 64, 479–482.
2. Rapp, U. R. (1991) Oncogene 6, 495–500.
3. Perrimon, N. (1993) Cell 74, 219–222.
4. Han, M., Golden, A., Han, Y., and Sternberg, P. W. (1993) Nature 363, 133–140.
5. Hallberg, G., Rayter, S., and Downward, J. (1994) J. Biol. Chem. 269, 3913–3916.
6. Köhle, H., Satoh, T., Nakafuku, M., and Kawai, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8683–8686.
7. Moodie, S. A., Williams, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658–1661.
8. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6213–6217.
9. Warne, P. H., Viclana, P. R., and Downward, J. (1994) Oncogene 21, 23753–23760.
10. Warne, P. H., Viclana, P. R., and Downward, J. (1993) Oncogene 6, 495–500.
11. Zhang, X., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., and Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993) Nature 364, 308–313.
12. Beer, T. W., Husein, M., Gunnell, M., Bonner, T. I., and Rapp, U. R. (1987) Nucleic Acids Res. 15, 595–609.
13. Storm, S. M., Cleveland, J. L., and Rapp, U. R. (1990) Oncogene 5, 345–351.
14. Marx, M., Eychene, A., Lauger, D., Béchade, C., Crisanti, P., Dezèlée, P., Pessac, B., and Calothy, G. (1988) EMBO J. 7, 3369–3373.
15. Ikawa, S., Fukui, M., Ueyama, Y., Tanakai, N., Yamanoto, T., and Toyoshima, K. (1990) Mol. Cell. Biol. 8, 2651–2654.
16. Oshima, M., Sithanandam, G., Rapp, U. R., and Guroff, G. (1991) J. Biol. Chem. 266, 23753–23760.
17. Stephens, R. M., Sithanandam, G., Copeland, T. D., Kaplan, D. R., Rapp, U. R., and Morrison, D. K. (1992) Mol. Cell. Biol. 12, 3733–3742.
18. Troppmair, J., Bruder, J. T., App, H., Cai, H., Liptak, L., Szepeney, J., Cooper, G. M., and Rapp, U. R. (1992) Oncogene 7, 1867–1873.
19. Lange-Carter, C. A., and Johnson, G. (1994) Science 265, 1458–1461.
20. Eychene, A., Dusant-Fourt, I., Béchade, C., Charon, M., Gisselbrecht, S., and Calothy, G. (1995) Oncogene 10, 1139–1165.
21. J. Arnouilh, F., Moodie, S. A., Wolfman, A., and Landreth, G. E. (1994) Mol. Cell. Biol. 14, 6944–6953.
22. Travers, S., and Cohen, P. (1994) FEBS Lett. 350, 13–18.
23. Moodie, S. A., Paris, M. J., Kitch, W., and Wolfman, A. (1994) Mol. Cell. Biol. 14, 7153–7162.
24. Catling, A. D., Reuter, C. W. M., Cox, M. E., Parson, S. J., and Weber, M. J. (1994), J. Biol. Chem. 269, 30014–30021.
25. Page, C. E., Eychene, A., Bruder, J. T., Pagès, P., Pouysségur, J., Calothy, G., and Béchade, C. (1995) Oncogene 10, 1647–1651.
26. Wadwitz, A. G., Winer, M. A., and Wolgemuth, D. J. (1993) Oncogene 8, 1055–1062.
27. Eychene, A., Béchade, C., Dezèlée, P., Marx, M., Lauger, D., Calogeraki, I., and Calothy, G. (1992a) Oncogene 7, 1315–1323.
28. Calogeraki, I., Béchade, C., Eychene, A., Fedler, M. P., Calothy, G., and Marx, M. (1993) Biochem. Biophys. Res. Commun. 203, 1324–1331.
29. Eychene, A., Béchade, C., Apiou, F., Dutrillaux, B., and Calothy, G. (1992b) Oncogene 7, 1657–1660.
30. Sithanandam, G., Kitch, W., Duh, F. M., and Rapp, U. R. (1990) Oncogene 5, 1775–1780.
31. Milhaly, A., Endrész, V., Oravecz, T., Rapp, U. R., and Kuhnt, W. (1993) Brain Res. 627, 225–236.
32. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) in Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
33. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156–159.
34. Renaud, E., Stensens, P., and Fiers, W. (1981) Gene (Amst.) 15, 81–93.
35. Ghysdael, J., Gégonne, A., Pognonec, P., Denis, D., Leprince, D., and Stéphelin, D. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 1714–1718.
36. Harlow, E., and Lane, D. (1988) in Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
37. Miki, T., Fleming, T. P., Crescenzi, M., Molloy, C. J., Blam, S. B., Reynolds, S. H., and Aaronsen, S. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5167–5171.
38. Breathnach, R., and Chambon, P. (1981) Nature 291, 329–337.
39. Srinivas, M., Edman, C. F., and Schulman, H. (1994) J. Cell Biol. 126, 839–852..
40. Fabian, J. R., Vojtek, A. B., Cooper, J. A., and Morrison, D. K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9582–9586.
41. Brugge, J. S., Cotton, P. C., Queral, E., Barret, J. N., Nonner, D., and Keane, T. W. (1985) Nature 316, 554–557.
42. Lamballe, F., Tapley, P., and Barbacid, M. (1993) EMBO J. 12, 3083–3090.